ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement

Table 3 Proportions of plasma EPA and DHA after treatment, stratified by ELOVL2 rs3734398 genotype

Treatment	n (TT/TC + CC)^a	EPA			DHA
Treatment	n (TT/TC + CC)^a	TT	TC + CC	P*	TT	TC + CC	P*
Placebo	22/44	1.00 (0.86,1.13)	0.96 (0.86,1.06)	0.941	2.23 (2.08,2.37)	2.22 (2.12,2.32)	0.714
0.45 g/day	19/50	2.01 (1.65,2.38)	1.78 (1.55,2.00)	0.180	3.02 (2.79,3.24)	2.83 (2.70,2.97)	0.035
0.90 g/day	26/48	2.52 (2.25,2.78)	2.25 (2.06,2.44)	0.018	3.36 (3.17,3.55)	3.34 (3.20,3.47)	0.282
1.80 g/day	22/47	3.34 (2.87,3.82)	4.20 (3.88,4.52)	0.003	3.90 (3.68,4.13)	4.24 (4.08,4.39)	0.016

Data show mean (95 % CI) follow-up values for EPA and DHA as a percentage of total fatty acids, adjusted for baseline. Subjects received supplements of EPA and DHA (1.51:1) at the daily doses shown for 6 month
EPA eicosapentaenoic acid; DHA docosahexaenoic acid
* Significance of genotype association with proportions of fatty acids with respect to SNP genotype based on a dominant model was tested by multivariate ANOVA. Interaction between genotype and treatment tested by univariate ANOVA was a significant determinant of EPA (P < 0.0001) and DHA (P = 0.008). All P-values were adjusted for baseline values, BMI, age, gender and ethnicity
^a n = number of subjects in genotype groups TT and TC + CC

ISSN: 1865-3499